SK284856B6 - Imunogénna molekula, farmaceutická kompozícia, ligand, spôsob prípravy imunogénnej molekuly a jej použitie - Google Patents

Imunogénna molekula, farmaceutická kompozícia, ligand, spôsob prípravy imunogénnej molekuly a jej použitie Download PDF

Info

Publication number: SK284856B6
Authority: SK; Slovakia
Prior art keywords: gly; peptide; bsw17; leu; ser
Prior art date: 1996-03-01

Application number

SK1181-98A

Other languages

English (en)

Slovak (sk)

Other versions

SK118198A3 (en

Inventor

Franz Kricek

Beda Stadler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-01

Filing date

1997-02-28

Publication date

2006-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26308839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284856(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-03-01 Priority claimed from GBGB9604412.8A external-priority patent/GB9604412D0/en

1996-08-22 Priority claimed from GBGB9617702.7A external-priority patent/GB9617702D0/en

1997-02-28 Application filed by Novartis Ag filed Critical Novartis Ag

1999-03-12 Publication of SK118198A3 publication Critical patent/SK118198A3/sk

2006-01-05 Publication of SK284856B6 publication Critical patent/SK284856B6/sk

Links

230000002163 immunogen Effects 0.000 title claims abstract description 40
238000002360 preparation method Methods 0.000 title claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
238000000034 method Methods 0.000 title claims description 17
239000003446 ligand Substances 0.000 title claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 187
230000028993 immune response Effects 0.000 claims abstract description 19
229960005486 vaccine Drugs 0.000 claims abstract description 18
206010020751 Hypersensitivity Diseases 0.000 claims abstract description 17
230000007815 allergy Effects 0.000 claims abstract description 11
238000011282 treatment Methods 0.000 claims abstract description 8
208000026935 allergic disease Diseases 0.000 claims abstract description 6
201000010099 disease Diseases 0.000 claims abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
235000001014 amino acid Nutrition 0.000 claims description 73
150000001413 amino acids Chemical class 0.000 claims description 72
230000027455 binding Effects 0.000 claims description 51
239000012634 fragment Substances 0.000 claims description 44
239000002671 adjuvant Substances 0.000 claims description 10
125000004122 cyclic group Chemical group 0.000 claims description 10
239000000863 peptide conjugate Substances 0.000 claims description 9
125000003275 alpha amino acid group Chemical group 0.000 claims description 8
210000004408 hybridoma Anatomy 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 4
102000037865 fusion proteins Human genes 0.000 claims description 4
108020001507 fusion proteins Proteins 0.000 claims description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
238000012545 processing Methods 0.000 claims description 2
XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 claims 1
LHRXAHLCRMQBGJ-RYUDHWBXSA-N Gly-Glu-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN LHRXAHLCRMQBGJ-RYUDHWBXSA-N 0.000 claims 1
230000008878 coupling Effects 0.000 claims 1
238000010168 coupling process Methods 0.000 claims 1
238000005859 coupling reaction Methods 0.000 claims 1
206010012438 Dermatitis atopic Diseases 0.000 abstract description 4
201000008937 atopic dermatitis Diseases 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 3
230000001404 mediated effect Effects 0.000 abstract 1
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 66
241000283973 Oryctolagus cuniculus Species 0.000 description 54
102000004196 processed proteins & peptides Human genes 0.000 description 54
239000000562 conjugate Substances 0.000 description 37
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 37
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 33
229960001340 histamine Drugs 0.000 description 33
210000002966 serum Anatomy 0.000 description 33
230000000692 anti-sense effect Effects 0.000 description 32
210000004027 cell Anatomy 0.000 description 32
239000000835 fiber Substances 0.000 description 32
230000003053 immunization Effects 0.000 description 32
238000002649 immunization Methods 0.000 description 31
239000000872 buffer Substances 0.000 description 26
108091003079 Bovine Serum Albumin Proteins 0.000 description 21
239000002245 particle Substances 0.000 description 19
229940098773 bovine serum albumin Drugs 0.000 description 18
230000021615 conjugation Effects 0.000 description 17
238000011534 incubation Methods 0.000 description 17
238000002965 ELISA Methods 0.000 description 15
210000003651 basophil Anatomy 0.000 description 13
210000003630 histaminocyte Anatomy 0.000 description 13
230000002052 anaphylactic effect Effects 0.000 description 12
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
230000003993 interaction Effects 0.000 description 11
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
239000005018 casein Substances 0.000 description 10
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 10
235000021240 caseins Nutrition 0.000 description 10
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
125000000539 amino acid group Chemical group 0.000 description 9
239000000427 antigen Substances 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
241001515965 unidentified phage Species 0.000 description 9
108010001336 Horseradish Peroxidase Proteins 0.000 description 8
239000004472 Lysine Substances 0.000 description 8
206010070834 Sensitisation Diseases 0.000 description 8
210000002798 bone marrow cell Anatomy 0.000 description 8
235000018417 cysteine Nutrition 0.000 description 8
230000008313 sensitization Effects 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
150000001945 cysteines Chemical class 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
241000283707 Capra Species 0.000 description 6
102000014914 Carrier Proteins Human genes 0.000 description 6
108010078791 Carrier Proteins Proteins 0.000 description 6
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 6
102000009438 IgE Receptors Human genes 0.000 description 6
108010073816 IgE Receptors Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 6
229960003669 carbenicillin Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
150000002617 leukotrienes Chemical class 0.000 description 6
238000005259 measurement Methods 0.000 description 6
102000009109 Fc receptors Human genes 0.000 description 5
108010087819 Fc receptors Proteins 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
230000000172 allergic effect Effects 0.000 description 5
230000003266 anti-allergic effect Effects 0.000 description 5
208000010668 atopic eczema Diseases 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000013049 sediment Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
239000013566 allergen Substances 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004132 cross linking Methods 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000002823 phage display Methods 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
239000004098 Tetracycline Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000011088 calibration curve Methods 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
241000894007 species Species 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229960002180 tetracycline Drugs 0.000 description 3
229930101283 tetracycline Natural products 0.000 description 3
235000019364 tetracycline Nutrition 0.000 description 3
150000003522 tetracyclines Chemical class 0.000 description 3
230000002792 vascular Effects 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
241000700605 Viruses Species 0.000 description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000011161 development Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
108060003552 hemocyanin Proteins 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
238000009630 liquid culture Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
TXOUDPQJASQYBZ-UHFFFAOYSA-N n,n'-dihexylmethanediimine Chemical compound CCCCCCN=C=NCCCCCC TXOUDPQJASQYBZ-UHFFFAOYSA-N 0.000 description 2
239000013642 negative control Substances 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960001005 tuberculin Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
241000244186 Ascaris Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000283153 Cetacea Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
FNAJNWPDTIXYJN-CIUDSAMLSA-N Gln-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O FNAJNWPDTIXYJN-CIUDSAMLSA-N 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
MXXXVOYFNVJHMA-IUCAKERBSA-N Gly-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN MXXXVOYFNVJHMA-IUCAKERBSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
NIKBMHGRNAPJFW-IUCAKERBSA-N His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 NIKBMHGRNAPJFW-IUCAKERBSA-N 0.000 description 1
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 description 1
QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
241001625930 Luria Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
101100026203 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) neg-1 gene Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
APJPXSFJBMMOLW-KBPBESRZSA-N Phe-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 APJPXSFJBMMOLW-KBPBESRZSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101100441500 Schizosaccharomyces pombe (strain 972 / ATCC 24843) saf4 gene Proteins 0.000 description 1
PBUXMVYWOSKHMF-WDSKDSINSA-N Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO PBUXMVYWOSKHMF-WDSKDSINSA-N 0.000 description 1
XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
239000007994 TES buffer Substances 0.000 description 1
AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
AOAMKFFPFOPMLX-BVSLBCMMSA-N Trp-Arg-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 AOAMKFFPFOPMLX-BVSLBCMMSA-N 0.000 description 1
SMDQRGAERNMJJF-JQWIXIFHSA-N Trp-Cys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CS)C(O)=O)=CNC2=C1 SMDQRGAERNMJJF-JQWIXIFHSA-N 0.000 description 1
YCQXZDHDSUHUSG-FJHTZYQYSA-N Trp-Thr-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 YCQXZDHDSUHUSG-FJHTZYQYSA-N 0.000 description 1
WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000009833 antibody interaction Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000001142 circular dichroism spectrum Methods 0.000 description 1
238000013377 clone selection method Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000000424 optical density measurement Methods 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
108010071207 serylmethionine Proteins 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SK1181-98A 1996-03-01 1997-02-28 Imunogénna molekula, farmaceutická kompozícia, ligand, spôsob prípravy imunogénnej molekuly a jej použitie SK284856B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9604412.8A GB9604412D0 (en)	1996-03-01	1996-03-01	Organic compounds
GBGB9617702.7A GB9617702D0 (en)	1996-08-22	1996-08-22	Organic compounds
PCT/EP1997/001013 WO1997031948A1 (en)	1996-03-01	1997-02-28	Peptide immunogens for vaccination against and treatment of allergy

Publications (2)

Publication Number	Publication Date
SK118198A3 SK118198A3 (en)	1999-03-12
SK284856B6 true SK284856B6 (sk)	2006-01-05

Family

ID=26308839

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1181-98A SK284856B6 (sk)	1996-03-01	1997-02-28	Imunogénna molekula, farmaceutická kompozícia, ligand, spôsob prípravy imunogénnej molekuly a jej použitie

Country Status (25)

Country	Link
US (1)	US6610297B1 (xx)
EP (1)	EP0885244B2 (xx)
JP (2)	JP3421970B2 (xx)
KR (2)	KR100498198B1 (xx)
CN (1)	CN1174998C (xx)
AT (1)	ATE230417T1 (xx)
AU (1)	AU719609B2 (xx)
BR (1)	BR9707819A (xx)
CA (1)	CA2245497C (xx)
CY (1)	CY2457B1 (xx)
CZ (1)	CZ299551B6 (xx)
DE (1)	DE69718150T3 (xx)
DK (1)	DK0885244T4 (xx)
ES (1)	ES2190799T5 (xx)
HK (1)	HK1014962A1 (xx)
HU (1)	HUP9901109A3 (xx)
IL (1)	IL125590A (xx)
NO (1)	NO321043B1 (xx)
NZ (1)	NZ331651A (xx)
PL (1)	PL187209B1 (xx)
RU (1)	RU2193413C2 (xx)
SI (1)	SI0885244T2 (xx)
SK (1)	SK284856B6 (xx)
TR (1)	TR199801722T2 (xx)
WO (1)	WO1997031948A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6913749B2 (en)	1998-11-02	2005-07-05	Resistentia Pharmaceuticals Ab	Immunogenic polypeptides for inducing anti-self IgE responses
EP1621209A3 (en) *	1998-11-02	2006-04-19	Resistentia Pharmaceuticals AB	Vaccines based on domains of chimeric immunoglobulin E peptides
CN100534529C (zh)	1998-11-30	2009-09-02	希托斯生物技术股份公司	抗原的有序分子呈递，制备及使用的方法
EP1156825A2 (en) *	1999-02-25	2001-11-28	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
TR200102493T2 (tr) *	1999-02-25	2002-02-21	Smithkline Beecham Biologicals S.A.	IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
GB9908533D0 (en) *	1999-04-14	1999-06-09	Novartis Ag	Organic compounds
IL152054A0 (en) *	2000-04-13	2003-05-29	Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh	Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
CA2407897A1 (en)	2000-05-05	2001-11-15	Cytos Biotechnology Ag	Molecular antigen arrays and vaccines
EP1967206B1 (en)	2000-08-30	2012-10-10	Pfizer Products Inc.	Anti-IgE vaccines
US7094409B2 (en)	2001-01-19	2006-08-22	Cytos Biotechnology Ag	Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en)	2001-01-19	2008-01-22	Cytos Biotechnology Ag	Molecular antigen array
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
EP1236740B1 (de) *	2001-02-28	2012-07-18	Bio Life Science Forschungs- und Entwicklungsges.m.b.H.	Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
EP1239032A1 (en) *	2001-03-02	2002-09-11	Société des Produits Nestlé S.A.	Lactic acid bacteria as agents for treating and preventing allergy
JP2003047482A (ja)	2001-05-22	2003-02-18	Pfizer Prod Inc	非アナフィラキシー誘発性ＩｇＥワクチン
AU2002326751A1 (en)	2001-08-13	2003-03-03	Ige Therapeutics, Inc.	Immunoglobulin e vaccines and methods of use thereof
US7115266B2 (en)	2001-10-05	2006-10-03	Cytos Biotechnology Ag	Angiotensin peptide-carrier conjugates and uses thereof
ES2286409T3 (es) *	2002-01-15	2007-12-01	Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh	Vacunacion oral con el mimotopo de antigeno tumoral gin-met-trp-ala-pro-gin-trp-gly-pro-asp.
EP1532167B1 (en)	2002-07-17	2012-01-25	Cytos Biotechnology AG	Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
AU2003250106B2 (en)	2002-07-18	2009-11-26	Cytos Biotechnology Ag	Hapten-carrier conjugates comprising virus like particles and uses thereof
CA2492930C (en)	2002-07-19	2013-01-08	Cytos Biotechnology Ag	Vaccine compositions containing amyloid beta1-6 antigen arrays
WO2004016750A2 (en)	2002-08-14	2004-02-26	Macrogenics, Inc.	FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US20050065136A1 (en) *	2003-08-13	2005-03-24	Roby Russell R.	Methods and compositions for the treatment of infertility using dilute hormone solutions
US20050239757A1 (en) *	2004-04-21	2005-10-27	Roby Russell R	Hormone treatment of macular degeneration
US20060025390A1 (en) *	2004-07-28	2006-02-02	Roby Russell R	Treatment of hormone allergy and related symptoms and disorders
ITMI20052517A1 (it) *	2005-12-29	2007-06-30	Lofarma Spa	Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
LT2029173T (lt)	2006-06-26	2016-11-10	Macrogenics, Inc.	Fc riib specifiniai antikūnai ir jų panaudojimo būdai
EP2012122A1 (en) *	2007-07-06	2009-01-07	Medigene AG	Mutated parvovirus structural proteins as vaccines
US8865179B2 (en) *	2008-01-26	2014-10-21	Swey-Shen Alexchen	Aptameric IgE peptides in a protein scaffold as an allergy vaccine
AU2009325950B2 (en)	2008-12-09	2013-03-07	Pfizer Vaccines Llc	IgE CH3 peptide vaccine
WO2011154878A1 (en)	2010-06-07	2011-12-15	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
RU2761431C9 (ru) *	2020-10-26	2022-04-18	Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России)	Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4171299A (en)	1975-04-04	1979-10-16	The Regents Of The University Of California	Polypeptide agents for blocking the human allergic response
DE2602443A1 (de)	1975-04-04	1976-10-21	Univ California	Biologisch aktive polypeptide
EP0000252B1 (en)	1977-06-29	1982-02-03	Beecham Group Plc	Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides
JPS5944399A (ja)	1982-09-07	1984-03-12	Takeda Chem Ind Ltd	新規ｄｎａ
GB8616166D0 (en) *	1986-07-02	1986-08-06	Research Corp Ltd	Polypeptide competitor
US4892827A (en)	1986-09-24	1990-01-09	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0269455A3 (en)	1986-11-28	1989-09-06	Takeda Chemical Industries, Ltd.	Highly purified fused protein comprising human ige fc fragment and production thereof
EP0344211A4 (en)	1987-02-20	1990-03-12	Imclone Systems Inc	MONOCLONAL ANTIBODIES IN VACCINE COMPOSITIONS.
CA1336818C (en)	1987-04-16	1995-08-29	International Institute Of Cellular And Molecular Pathology	Treatment of allergy and composition thereof
ATE152244T1 (de)	1987-10-13	1997-05-15	Terrapin Tech Inc	Verfahren zur herstellung von imunodiagnose- mitteln
GB8727045D0 (en)	1987-11-19	1987-12-23	Research Corp Ltd	Immunoglobulin e competitor
US5449760A (en)	1987-12-31	1995-09-12	Tanox Biosystems, Inc.	Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5342924A (en)	1987-12-31	1994-08-30	Tanox Biosystems, Inc.	Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
GB8910263D0 (en)	1989-05-04	1989-06-21	Ciba Geigy Ag	Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) *	1989-06-15	1989-08-02	Univ Birmingham	A novel anti-allergy treatment
EP0512064B1 (en)	1990-01-23	1997-06-18	Tanox Biosystems, Inc.	Extracellular segments of human ige immunoglobulin anchoring peptides and antibodies specific therefor
GB2246780B (en)	1990-05-25	1994-04-27	Nat Res Dev	Immunodiagnostic assay for rheumatoid arthritis
US5258289A (en)	1990-09-05	1993-11-02	Davis Claude G	Method for the selecting of genes encoding catalytic antibodies
GB9101550D0 (en)	1991-01-24	1991-03-06	Mastico Robert A	Antigen-presenting chimaeric protein
US5965709A (en) *	1991-08-14	1999-10-12	Genentech, Inc.	IgE antagonists
AU2498192A (en) *	1991-08-14	1993-03-16	Genentech Inc.	Immunoglobulin variants for specific fc epsilon receptors
SE9102808L (sv)	1991-09-26	1993-03-27	Lars T Hellman Inst F Immunolo	Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
GB9125024D0 (en)	1991-11-25	1992-01-22	Kirby Julian	Rheumatoid arthritus treatment
JPH06113881A (ja)	1992-10-07	1994-04-26	Snow Brand Milk Prod Co Ltd	ヒト型モノクローナル抗ペプチド抗体及びこれをコードするｄｎａ
DE69431114T2 (de)	1993-04-27	2003-03-13	United Biomedical, Inc.	Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe
US5759551A (en)	1993-04-27	1998-06-02	United Biomedical, Inc.	Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
EP0763537A3 (en)	1993-05-14	1997-10-22	Genentech Inc	Non-peptides farnesyl transfer inhibitors
GB9320897D0 (en)	1993-10-11	1993-12-01	Peptide Therapeutics Ltd	Compounds useful in anti-allergy treatment
GB9324013D0 (en) *	1993-11-22	1994-01-12	3I Res Expl Ltd	Polypeptides
FR2715304B1 (fr) *	1994-01-26	1996-04-26	Merieux Serums Vaccins Pasteur	Vaccin anti-allergique.
CA2186595A1 (en) *	1994-03-28	1995-10-05	Chang Yi Wang	Synthetic peptide based immunogens for the treatment of allergy
WO1996001643A1 (en)	1994-07-08	1996-01-25	Thomas Jefferson University	IgE ANTAGONISTS
CN1167491A (zh)	1994-10-25	1997-12-10	美国联合生物医学公司	用于治疗变态反应的合成IgE膜锚肽免疫原
WO1998024808A2 (en)	1996-12-06	1998-06-11	THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH	INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
EP0955311A3 (en)	1998-04-09	2000-08-16	Idexx Laboratories, Inc.	Peptide vaccine for canine allergy
TWI229679B (en)	1998-06-20	2005-03-21	United Biomedical Inc	Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens

1997
- 1997-02-28 HU HU9901109A patent/HUP9901109A3/hu unknown
- 1997-02-28 PL PL97328858A patent/PL187209B1/pl not_active IP Right Cessation
- 1997-02-28 CA CA002245497A patent/CA2245497C/en not_active Expired - Fee Related
- 1997-02-28 EP EP97905136A patent/EP0885244B2/en not_active Expired - Lifetime
- 1997-02-28 RU RU98118184/14A patent/RU2193413C2/ru not_active IP Right Cessation
- 1997-02-28 CN CNB971926719A patent/CN1174998C/zh not_active Expired - Fee Related
- 1997-02-28 US US09/125,641 patent/US6610297B1/en not_active Expired - Fee Related
- 1997-02-28 CZ CZ0277198A patent/CZ299551B6/cs not_active IP Right Cessation
- 1997-02-28 KR KR10-1998-0706845A patent/KR100498198B1/ko not_active IP Right Cessation
- 1997-02-28 KR KR1020057005577A patent/KR100584051B1/ko not_active IP Right Cessation
- 1997-02-28 IL IL12559097A patent/IL125590A/xx not_active IP Right Cessation
- 1997-02-28 SI SI9730490T patent/SI0885244T2/sl unknown
- 1997-02-28 NZ NZ331651A patent/NZ331651A/xx unknown
- 1997-02-28 DK DK97905136T patent/DK0885244T4/da active
- 1997-02-28 DE DE69718150T patent/DE69718150T3/de not_active Expired - Lifetime
- 1997-02-28 TR TR1998/01722T patent/TR199801722T2/xx unknown
- 1997-02-28 BR BR9707819A patent/BR9707819A/pt not_active Application Discontinuation
- 1997-02-28 SK SK1181-98A patent/SK284856B6/sk unknown
- 1997-02-28 AU AU18796/97A patent/AU719609B2/en not_active Ceased
- 1997-02-28 WO PCT/EP1997/001013 patent/WO1997031948A1/en active IP Right Grant
- 1997-02-28 JP JP53063297A patent/JP3421970B2/ja not_active Expired - Fee Related
- 1997-02-28 ES ES97905136T patent/ES2190799T5/es not_active Expired - Lifetime
- 1997-02-28 AT AT97905136T patent/ATE230417T1/de not_active IP Right Cessation
1998
- 1998-08-31 NO NO19983999A patent/NO321043B1/no unknown
- 1998-12-31 HK HK98119259A patent/HK1014962A1/xx not_active IP Right Cessation
2002
- 2002-12-26 JP JP2002377664A patent/JP2003231696A/ja active Pending
2004
- 2004-06-04 CY CY0400044A patent/CY2457B1/xx unknown

Also Published As

Publication number	Publication date
HK1014962A1 (en)	1999-10-08
KR100498198B1 (ko)	2005-09-09
KR19990087425A (ko)	1999-12-27
RU2193413C2 (ru)	2002-11-27
PL328858A1 (en)	1999-03-01
EP0885244B2 (en)	2008-04-16
HUP9901109A3 (en)	1999-11-29
NZ331651A (en)	2000-01-28
TR199801722T2 (xx)	1998-12-21
ES2190799T3 (es)	2003-08-16
SI0885244T1 (en)	2003-06-30
EP0885244B1 (en)	2003-01-02
AU719609B2 (en)	2000-05-11
AU1879697A (en)	1997-09-16
NO983999L (no)	1998-11-02
JP2003231696A (ja)	2003-08-19
IL125590A0 (en)	1999-03-12
JP3421970B2 (ja)	2003-06-30
DE69718150D1 (de)	2003-02-06
WO1997031948A1 (en)	1997-09-04
KR20050049509A (ko)	2005-05-25
CZ277198A3 (cs)	1998-12-16
CZ299551B6 (cs)	2008-08-27
ATE230417T1 (de)	2003-01-15
DK0885244T3 (da)	2003-04-22
CN1174998C (zh)	2004-11-10
CA2245497A1 (en)	1997-09-04
KR100584051B1 (ko)	2006-05-30
CN1213380A (zh)	1999-04-07
PL187209B1 (pl)	2004-06-30
SI0885244T2 (sl)	2008-10-31
CY2457B1 (en)	2005-06-03
ES2190799T5 (es)	2008-08-16
BR9707819A (pt)	1999-07-27
NO983999D0 (no)	1998-08-31
SK118198A3 (en)	1999-03-12
HUP9901109A2 (hu)	1999-07-28
NO321043B1 (no)	2006-03-06
DE69718150T3 (de)	2009-03-05
DK0885244T4 (da)	2008-06-16
DE69718150T2 (de)	2003-08-21
EP0885244A1 (en)	1998-12-23
US6610297B1 (en)	2003-08-26
IL125590A (en)	2001-08-26
CA2245497C (en)	2009-02-24
JP2000502571A (ja)	2000-03-07

Publication	Publication Date	Title
US6610297B1 (en)	2003-08-26	Peptide immunogens for vaccination against and treatment of allergy
KR0181313B1 (ko)	1999-04-01	면역활성 펜티드 및 항체와 이것들의 항-알레르기 치료에의 이용
CZ20013081A3 (cs)	2002-02-13	Epitopy a mimotopy získané z oblastí C-epsilon-2 nebo C-epsilon-4 IgE, jejich antagonisté a jejich terapeutické pouľití
Terness et al.	1995	The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope.
EP1169353B1 (en)	2008-04-16	Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
KR20020007313A (ko)	2002-01-26	ＩｇＥ의 Ｃ-엡실론-2 도메인으로부터 유도된 에피토프또는 미모토프, 이들의 길항제 및 이들의 치료학적 용도
US20030147906A1 (en)	2003-08-07	Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of lgE, antagonists thereof, and their therapeutic uses
US20030170229A1 (en)	2003-09-11	Vaccine
US20050214285A1 (en)	2005-09-29	Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
US7250164B2 (en)	2007-07-31	Vaccine composition for preventing meningococcal disease